Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens

Journal of Clinical Oncology

Volumn 18, Issue 12, 2000, Pages 2354-2362

  Fossella, Frank V ^a   DeVore, Russell ^a   Kerr, Ronald N ^a   Crawford, Jeffrey ^a   Natale, Ronald R ^a   Dunphy, Frank ^a   Kalman, Leonard ^a   Miller, Vincent ^a   Lee, Jin Soo ^a   Moore, Melvin ^a   Gandara, David ^a   Karp, Daniel ^a   Vokes, Everett ^a   Kris, Mark ^a   Kim, Yong ^a   Gamza, Francis ^a   Hammershaimb, Luz ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; IFOSFAMIDE; NAVELBINE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROTOXICITY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; TREATMENT INDICATION; VOMITING;

EID: 0034095853     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.12.2354     Document Type: Article

References (32)

1. Landis SH, Murray T, Bolden S, et al: Cancer statistics, 1998. CA Cancer J Clin 48:6-29, 1998
2. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311:899-909, 1995
3. Grilli R, Oxman AD, Julian JA: Chemotherapy for advanced non-small-cell lung cancer: How much benefit is enough? J Clin Oncol 11:1866-1872, 1993
4. Fossella FV, Lee JS, Hong WK: Management strategies for recurrent non-small cell lung cancer. Semin Oncol 24:455-462, 1997
5. Fossella FV, Lee JS, Shin DM, et al: Phase II study of docetaxel for advanced or metastatic platinum refractory non-small cell lung cancer. J Clin Oncol 13:645-651, 1995
6. Burris H, Eckardt J, Fields S, et al: Phase II trials of Taxotere with non-small cell lung cancer. Proc Am Soc Clin Oncol 12: 335a, 1993 (abstr 1116)
7. Gandara DR, Vokes E, Green M, et al: Docetaxel (Taxotere) in platinum-treated non-small cell lung cancer: A confirmation of prolonged survival in a multicenter trial. Proc Am Soc Clin Oncol 16:454a, 1997 (abstr 1632)
8. Robinet G, Kleisbauer JP, Thomas P, et al: Phase II study of docetaxel (Taxotere) in first- and second-line NSCLC. Proc Am Soc Clin Oncol 16:480a, 1997 (abstr 1726)
9. Hopwood P: Evidence for the impact of quality of life. Lung Cancer 18:66, 1997 (suppl 2)
10. Moinpour D, Feign P, Mech B, et al: Quality of life end points in cancer clinical trials: Review and recommendations. J Natl Cancer Inst 81:485-495, 1989
11. Hollen P, Gralla R, Kris M, et al: Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer 29A: S51-S58, 1993 (suppl 1)
12. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47:207-214, 1981
13. Hainsworth JD, Thompson DA, Greco FA: Paclitaxel by 1-hour infusion: An active drug in metastatic non-small-cell lung cancer. J Clin Oncol 13:1609-1614, 1995
14. Murphy WK, Winn RJ, Huber M, et al: Phase II study of Taxol in patients with non-small cell lung cancer who have failed platinum containing chemotherapy. Proc Am Soc Clin Oncol 13:363a, 1994 (abstr 1224)
15. Socinski MA, Steagall A, Gillenwater H: Second-line chemotherapy with 96-hour infusional paclitaxel in refractory non-small cell lung cancer: Report of a phase II trial. Cancer Invest 17:181-188, 1999
16. Roa V, Conner A, Mitchell RB: Carboplatin and paclitaxel for advanced non-small cell lung cancer in previously treated patients. Proc Am Soc Clin Oncol 15:403a, 1996 (abstr 1229)
17. Stewart DJ, Tomiak E, Goss G, et al: Paclitaxel plus low dose hydroxyurea as second line therapy in non-small cell lung cancer. Proc Am Soc Clin Oncol 14:367a, 1995 (abstr 1126)
18. Tan V, Herrera C, Einzig AI, et al: Taxol is active as a 3 hour or 24 hour infusion in non-small cell lung cancer. Proc Am Soc Clin Oncol 14:366a, 1995 (abstr 1122)
19. Ruckdeschel J, Wagner H, Williams C, et al: Second-line chemotherapy for resistant metastatic non-small cell lung cancer: The role of Taxol. Proc Am Soc Clin Oncol 13:357a, 1994 (abstr 1200)
20. Pronzato P, Landucci M, Vaira F, et al: Failure of vinorelbine to produce responses in pretreated non-small cell lung cancer patients. Anticancer Res 14:1413-1416, 1994
21. Rinaldi M, Della Giulia M, Venturo I, et al: Vinorelbine as single agent in the treatment of advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 13:360a, 1994 (abstr 1212)
22. Santoro A, Maiorino L, Santoro M: Second-line chemotherapy with vinorelbine in the weekly monochemotherapy for the treatment of advanced non-small cell lung cancer. Lung Cancer 11:130, 1994 (suppl 1, abstr 497)
23. Crino L, Mosconi AM, Scagliotti G, et al: Gemcitabine as second-line treatment for advanced non-small cell lung cancer: A phase II trial. J Clin Oncol 17:2081-2085, 1999
24. Rosvold E, Langer CJ, Schilder R, et al: Salvage therapy with gemcitabine in advanced non-small cell lung cancer (NSCLC) progressing after prior carboplatin-paclitaxel. Proc Am Soc Clin Oncol 17:467a, 1998 (abstr 1797)
25. Guerra JA, Lianes P, Paz-Ares L, et al: Efficacy and toxicity profile of gemcitabine in previously treated patients with non-small cell lung cancer (NSCLC). Lung Cancer 18:28, 1997 (suppl 1, abstr 99)
26. Garfield DH, Dakhil SR, Whittaker TL, et al: Phase II randomized multicenter trial of two dose schedules of gemcitabine as second line therapy in patients with advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 17:484a, 1998 (abstr 1863)
27. Fukuoka M, Takada M, Yokoyama A, et al: Phase II studies of gemcitabine for non-small cell lung cancer in Japan. Semin Oncol 24:S7-42-S7-46, 1997 (suppl 7)
28. Nakai H, Fukuoka M, Furuse K, et al: An early phase II study of CPT-11 for primary lung cancer. Jpn J Cancer Chemother 18:607-612, 1991
29. Niitani H, Fukuoka M, Nagao K: Clinical development of irinotecan (CPT-11) in lung cancers. Lung Cancer 11:30-31, 1994 (suppl 2)
30. Miller VA, Fossella FV, DeVore R, et al: Docetaxel benefits lung cancer symptoms and quality of life in a randomized phase III trial of non-small cell lung cancer patients previously treated with platinum-based therapy. Proc Am Soc Clin Oncol 18:491a, 1999 (abstr 1895)
31. Shepherd F, Ramlau R, Mattson K, et al: Randomized study of Taxotere versus best supportive care in non-small cell lung cancer patients previously treated with platinum-based chemotherapy. Proc Am Soc Clin Oncol 18:463a, 1999 (abstr 1784)
32. Dancey J, Shepherd F, Ramlau R, et al: Quality of life assessment in a randomized study of Taxotere versus best supportive care in non-small cell lung cancer patients previously treated with platinum-based chemotherapy. Proc Am Soc Clin Oncol 18:491a, 1999 (abstr 1896)